Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial

发表于 2026-7-17 11:53:15

期刊：Journal of Clinical Oncology

文献作者：Hong-Hu Zhu; De-Pei Wu; Jie Jin; Jian-Yong Li; Jun Ma; Jian-Xiang Wang; Hao Jiang; Sai-Juan Chen; Xiao-Jun Huang

出版日期：2013-11-20

DOI号：10.1200/jco.2013.48.8312

下载链接：https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2013.48.8312

文献链接：https://doi.org/10.1200/jco.2013.48.8312

当前文献来源于 American Society of Clinical Oncology (ASCO)。

备注信息：

发表于 2026-7-17 11:53:16

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[ASCO] Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[ASCO] Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial 一键复制